Chennai Journal

Sporadic Inclusion Body Myositis (sIBM) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Sporadic Inclusion Body Myositis (sIBM) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 26
21:06 2021
Sporadic Inclusion Body Myositis (sIBM) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Sporadic Inclusion Body Myositis (sIBM) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Sporadic Inclusion Body Myositis (sIBM) , historical and forecasted epidemiology as well as the Sporadic Inclusion Body Myositis (sIBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Sporadic Inclusion Body Myositis (sIBM) -Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Sporadic Inclusion Body Myositis (sIBM)  – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Sporadic Inclusion Body Myositis (sIBM) , historical and forecasted epidemiology as well as the  Sporadic Inclusion Body Myositis (sIBM)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. A male predominance and a prevalence of 1–71 people per million inhabitants has been reported in different populations, rising up to 139 per million among people over 50 years old as per a study.

  2. As per Orphanet, Prevalence of IBM in the general population ranges from 1:1,000,000 to 1:14,000 but a three-fold increase is observed when considering only a population over 50 years. Underdiagnosis may be an explanation for the high ethno-geographic variation. Male-to-female ratio is 2:1 on average (0.5 to 6.5:1). 

  3. As per organisation, IBM affects males slightly more often than females. Its prevalence is estimated to be between 10-112 people per 1,000,000 in the general population. It occurs with greater frequency in individuals more than 50 years of age. The prevalence is estimated to be 51–139 per 1,000,000 individuals in the general population over 50, making sIBM the most common acquired muscle disorder (myopathy) in that age group. 

Key benefits of the report:

1. Sporadic Inclusion Body Myositis (sIBM) market report covers a descriptive overview and comprehensive insight of the Sporadic Inclusion Body Myositis (sIBM)  epidemiology and Sporadic Inclusion Body Myositis (sIBM) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Sporadic Inclusion Body Myositis (sIBM) market report provides insights on the current and emerging therapies.

3. Sporadic Inclusion Body Myositis (sIBM) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Sporadic Inclusion Body Myositis (sIBM) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Sporadic Inclusion Body Myositis (sIBM) market.

Request for sample pages: https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market

Sporadic Inclusion Body Myositis (sIBM): Overview

Sporadic inclusion body myositis (sIBM) is the most commonly acquired myopathy in patients over the age of 50. More men have inclusion body myositis than women, and the disease is rarely seen in people younger than 50 years of age.

Inclusion body myositis is unlike all other forms of myositis in terms of symptoms, treatment, and who it affects.  Symptoms of inclusion body myositis progress more slowly than the other types of myositis with weakness increasing gradually, sometimes over years. For this reason it is not uncommon for patients to realize that they had been experiencing symptoms for many years before they were diagnosed.

The key players involved in the Sporadic Inclusion Body Myositis (sIBM) market:

  1. Novartis

  2. Orphazyme

  3. Dalazatide

The launch of the emerging therapies is expected to significantly impact the  Sporadic Inclusion Body Myositis (sIBM)  treatment scenario in the upcoming years:-

Drug covered

  1. Bimagrumab (BYM338) 

  2. Arimoclomol

  3. Kv1.3 Therapeutics 

Request a free sample report @https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Sporadic Inclusion Body Myositis (sIBM) Patient Share (%) Overview at a Glance

5. Sporadic Inclusion Body Myositis (sIBM) Market Overview at a Glance

6. Sporadic Inclusion Body Myositis (sIBM) Disease Background and Overview

7. Sporadic Inclusion Body Myositis (sIBM) Epidemiology and Patient Population

8. Country-Specific Patient Population of Sporadic Inclusion Body Myositis (sIBM) 

9. Sporadic Inclusion Body Myositis (sIBM) Current Treatment and Medical Practices

10. Unmet Needs

11. Sporadic Inclusion Body Myositis (sIBM) Emerging Therapies

12. Sporadic Inclusion Body Myositis (sIBM) Market Outlook

13. Country-Wise Sporadic Inclusion Body Myositis (sIBM) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Sporadic Inclusion Body Myositis (sIBM) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Sporadic Inclusion Body Myositis (sIBM)- Pipeline Insights, 2021

Sporadic Inclusion Body Myositis (sIBM)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sporadic Inclusion Body Myositis (sIBM) market. A detailed picture of the Sporadic Inclusion Body Myositis (sIBM) pipeline landscape is provided, which includes the disease overview and Sporadic Inclusion Body Myositis (sIBM) treatment guidelines.

Sporadic Inclusion Body Myositis (sIBM) -Epidemiology Forecast to 2030

DelveInsight’s ‘Sporadic Inclusion Body Myositis (sIBM) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Sporadic Inclusion Body Myositis (sIBM){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles